Drug Trial Radar · NCT02494986
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 6, 2015
Primary completion
Aug 18, 2026
Study completion Aug 18, 2026
Sponsor
- Lead sponsor
- Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jul 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 0 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.
Conditions
- Human Immunodeficiency Virus Type 1
Interventions
RilpivirineDrug
Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) related to rilpivirine (RPV)Time frame: Up to 32 Days from the last dose administered (Approximately 16 years)
- Number of Participants with AEs Leading to DiscontinuationTime frame: Up to 32 Days from the last dose administered (Approximately 16 years)
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 32 Days from the last dose administered (Approximately 16 years)
- Number of Participants with PregnanciesTime frame: Up to 32 Days from the last dose of administered (Approximately 16 years)
- Number or Participants with Grade 3/4 Rash Regardless of CausalityTime frame: Up to 32 Days from the last dose administered (Approximately 16 years)
Locations
8 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Porto, Portugal
Site not named
Bloemfontein, South Africa
Site not named
Dundee, South Africa
Site not named
Esplugues de Llobregat, Spain
Site not named
Bangkok, Thailand
Site not named
Nonthaburi, Thailand
Site not named
Entebbe, Uganda
Site not named
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.